Cybin, Inc.
(Aequitas NEO Exchange : CYBN)

( )
CYBN After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson -0.43%166.860.7%$1081.06m
PFEPfizer Inc. -1.38%48.590.9%$912.26m
LLYEli Lilly & Co. 0.04%316.961.1%$820.24m
MRKMerck & Co., Inc. 0.42%91.420.7%$782.30m
ABBVAbbVie, Inc. -0.04%141.391.9%$776.62m
BMYBristol-Myers Squibb Co. -0.55%74.151.0%$614.48m
SIGASIGA Technologies, Inc. -6.42%23.180.0%$439.36m
AZNAstraZeneca Plc 0.12%66.501.0%$365.07m
GBTGlobal Blood Therapeutics, Inc. 0.08%67.055.6%$352.06m
GSKGSK Plc -0.17%34.250.3%$285.96m
ALNYAlnylam Pharmaceuticals, Inc. 0.14%223.458.2%$270.68m
HZNPHorizon Therapeutics Plc -0.84%61.215.4%$225.68m
CCXIChemoCentryx, Inc. 0.43%51.002.9%$213.70m
KRTXKaruna Therapeutics, Inc. -0.08%261.010.0%$204.69m
VERUVeru, Inc. -21.47%18.680.0%$196.18m

Company Profile

Cybin, Inc. is an ethical biopharmaceutical company engaged in the development of therapeutics for patients to address a multitude of mental health issues. It is focused on progressing psychedelics to therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches, and treatment regimens for mental health disorders. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.